Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Westlake Frequent-sampling Cohort 2 (WeF2)

19 de maio de 2026 atualizado por: Westlake University
This observational follow-up study extends a previously completed 15-day intensive longitudinal study (WeF) of the gut microbiome in healthy adults. The objective of WeF2 is to characterize the long-term stability and dynamics of the gut and oral microbiota in the same cohort across multiple timescales, and to determine whether the day-to-day variability patterns observed at baseline persist over months and years. Participants who completed the WeF baseline protocol will be invited to attend periodic follow-up visits for low-frequency biospecimen collection and to repeat the original 15-day high-frequency sampling protocol at planned intervals, beginning approximately six months after the WeF baseline and continuing at extended intervals thereafter. By combining sparse routine sampling with recurring high-density sampling windows, the study aims to distinguish the stable core microbiome from transient and seasonal fluctuations, to track gradual community shifts under free-living conditions, and to further explore relationships among microbiome dynamics, dietary intake, and host glycemic regulation over an extended observation period.

Visão geral do estudo

Status

Recrutamento

Descrição detalhada

WeF2 is a non-interventional, observational follow-up study conducted in the cohort of healthy adult volunteers who completed the WeF baseline protocol. The study is designed to extend the temporal resolution of the original investigation from a single 15-day window to a multi-year horizon that interleaves low- and high-frequency sampling phases, allowing direct comparison of within-subject microbiome dynamics across short, medium, and long timescales. The overall follow-up duration is open-ended in design, with the intention that participants may continue to contribute to the cohort for as long as they remain willing and eligible.

The study is organized around two complementary sampling modes that recur throughout the follow-up period.

The routine follow-up mode consists of brief periodic visits, planned at approximately monthly intervals during the intervals between intensive sampling windows. At each routine visit, a single stool sample and a saliva sample are collected for microbial sequencing and functional evaluation, together with basic health and lifestyle information covering items such as recent dietary patterns, medication and supplement use, antibiotic exposure, illness, travel, and notable lifestyle changes since the previous visit. The exact content and cadence of these routine visits may be adjusted over the course of the study to reflect emerging scientific priorities, participant burden considerations, and operational feasibility, while preserving the core objective of capturing gradual community shifts and flagging transient perturbations occurring between intensive windows.

The intensive sampling mode replicates the original 15-day WeF protocol in full and is scheduled to recur at planned long-interval timepoints. The first intensive follow-up window is conducted approximately six months after completion of the WeF baseline; a second intensive window is planned approximately six months after the first (i.e., approximately one year after the WeF baseline); and additional intensive windows may be conducted at extended intervals thereafter as the cohort is maintained. Each intensive window involves daily collection of stool and saliva samples; collection of representative samples from meals consumed during the period for DNA sequencing of food sources, providing an objective record of dietary intake; and continuous blood glucose monitoring via a wearable CGM device throughout the 15 days. By holding the intensive protocol methodologically consistent with the WeF baseline, each intensive window produces a directly comparable dataset at the level of individual taxa, community structure, dietary signatures, and glycemic responses.

Routine follow-up visits continue in the periods between intensive windows, including after each intensive window has concluded, so that the cohort is observed under a continuous low-frequency framework punctuated by recurring high-frequency snapshots.

Integrating these sampling modes produces a longitudinal dataset that supports several complementary analyses: characterization of the temporal stability of the core microbiota across months and years; assessment of whether the magnitude and structure of day-to-day variability observed at baseline are reproducible at later timepoints; differentiation of intra-individual fluctuations from inter-individual differences across an expanded observation period; identification of seasonal or longer-cycle patterns in microbiome composition; and exploration of how dietary inputs and glycemic patterns relate to microbial dynamics on daily, monthly, and annual scales.

To ensure data integrity and participant safety, the study is overseen by a Data and Safety Monitoring Board and adheres to ethical standards approved by the Westlake University Ethics Committee, consistent with the framework established for the WeF baseline study.

Tipo de estudo

Observacional

Inscrição (Estimado)

20

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • Zhejiang
      • Hangzhou, Zhejiang, China, 310024

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto

Aceita Voluntários Saudáveis

Sim

Método de amostragem

Amostra Não Probabilística

População do estudo

Healthy young adults residing in Hangzhou

Descrição

Inclusion Criteria:

  • Participants reside in Hangzhou

Exclusion Criteria:

  • Refusing or unable to give informed consent
  • Participants with chronic gastrointestinal diseases and take daily relevant medications
  • Participants with metabolic diseases including diabetes, hypertension and cardiovascular diseases (CVD)
  • Participants with craniocerebral trauma, cancer, liver disease, kidney disease, or other critical illness, or history of operation or medication
  • Participants with bulimia nervosa, post-traumatic stress disorder (PTSD), chronic anxiety and depression or other critical neuronal disorder or history of relevant medication
  • Being or to be pregnant or lactating.
  • Participants with history of alcohol or drug addiction, or smoke above 15 cigarettes per day
  • Concurrently participating other clinical trials.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Gut microbiome
Prazo: 3 years
Description: Using qPCR, metagenomics, metabolomics, proteomics, and culturomics, we quantified the composition and absolute abundance of the gut microbiota and characterized its short-term and long-term dynamics.
3 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Ju-Sheng Zheng, PhD, Westlake University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

8 de maio de 2026

Conclusão Primária (Estimado)

8 de maio de 2027

Conclusão do estudo (Estimado)

31 de dezembro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

19 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de maio de 2026

Primeira postagem (Real)

26 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

26 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

19 de maio de 2026

Última verificação

1 de abril de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Outros números de identificação do estudo

  • 20260420ZJS001

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever